QPI 1007

Drug Profile

QPI 1007

Alternative Names: QPI-1007; siCASP2

Latest Information Update: 02 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Quark Pharmaceuticals
  • Developer Biocon; Kunshan RiboQuark Pharmaceutical Technology Co; Quark Pharmaceuticals
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action Caspase 2 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic nerve disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Optic nerve disorders
  • Phase II Angle-closure glaucoma

Most Recent Events

  • 29 Jul 2016 Quark Pharmaceuticals has patent protection for QPI 1007 in USA
  • 23 Jun 2016 Phase-II/III clinical trials in Optic nerve disorders in India, Israel, Germany, Australia, Italy, China (Intravitreous)
  • 14 Mar 2016 Quark Pharmaceuticals receives approval from the China Food and Drug Administration and Drug Controller General of India for a phase II/III trial of QPI 1007 for Optic nerve disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top